Section Arrow
CCCC.NASDAQ
- C4 Therapeutics
Quotes are at least 15-min delayed:2026/04/02 20:07 EDT
Regular Hours
Last
 2.82
+0.12 (+4.44%)
Day High 
2.84 
Prev. Close
2.7 
1-M High
3.82 
Volume 
2.13M 
Bid
2.74
Ask
2.83
Day Low
2.6001 
Open
2.63 
1-M Low
2.3 
Market Cap 
261.67M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.58 
20-SMA 2.76 
50-SMA 2.41 
52-W High 3.82 
52-W Low 1.085 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.27/-1.10
Enterprise Value
315.28M
Balance Sheet
Book Value Per Share
2.63
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
35.95M
Operating Revenue Per Share
0.21
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
COCPCocrystal Pharma1.51+0.49+48.04%-- 
BDRXBiodexa Pharmaceuticals plc0.8733+0.2593+42.23%-- 
IOBTIO Biotech0.0323-0.0114-26.09%-- 
GERNGeron Corp1.66------ 
ELABPmgc Holdings Inc5.72-8.28-59.14%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.